Literature DB >> 25825437

Impaired dendritic cell function in a spontaneous autoimmune polyneuropathy.

Songhua Quan1, Hye-Jung Kim2, Danuta Dukala1, Jian Rong Sheng1, Betty Soliven3.   

Abstract

Spontaneous autoimmune polyneuropathy (SAP) in B7-2 knockout NOD mice mimics the progressive form of chronic inflammatory demyelinating polyradiculoneuropathy, and is mediated by myelin protein zero (P0)-reactive Th1 cells. In this study, we focused on the effect of B7-2 deletion on the function of dendritic cells (DCs) within the context of SAP. We found that development of SAP was associated with a preponderance or increase of CD11b(+) DCs in peripheral lymph nodes and sciatic nerves. B7-2 deletion led to altered immunophenotypic properties that differ between CD11b(+) DCs and CD8α(+) DCs. Both DC subsets from B7-2 knockout NOD mice exhibited impaired capacity to capture fluorophore-labeled myelin P0, but diminished Ag-presenting function was observed only in CD11b(+) DCs. Clinical assessment, electrophysiologic studies, and splenocyte proliferation studies revealed that absence of B7-2 on DCs was sufficient to cause impaired ability to induce tolerance to P0, which could be overcome by preconditioning with IL-10. Tolerance induction by Ag-pulsed wild-type NOD DCs was dependent on IL-10 and was associated with increased CD4(+) regulatory T cells, whereas tolerance induction by IL-10-conditioned B7-2-deficient DCs was associated with increased percentages of both regulatory T cells and B10 cells in the spleen. We conclude that B7-2 deletion has an impact on the distribution of DC subsets in lymphoid organs and alters the expression of costimulatory molecules, but functional consequences are not uniform across DC subsets. Defective tolerance induction in the absence of B7-2 can be restored by preconditioning of DCs with IL-10.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825437      PMCID: PMC4402272          DOI: 10.4049/jimmunol.1401766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

Authors:  Samantha L Bailey; Bettina Schreiner; Eileen J McMahon; Stephen D Miller
Journal:  Nat Immunol       Date:  2007-01-07       Impact factor: 25.606

2.  CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.

Authors:  P M Abraham; S H Quan; D Dukala; B Soliven
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 3.  DC subsets in positive and negative regulation of immunity.

Authors:  Caroline Coquerelle; Muriel Moser
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

4.  T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis.

Authors:  A H Cross; J A Lyons; M San; R M Keeling; G Ku; M K Racke
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

5.  CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells.

Authors:  Sayuri Yamazaki; Diana Dudziak; Gordon F Heidkamp; Christopher Fiorese; Anthony J Bonito; Kayo Inaba; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

6.  B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets.

Authors:  Deepak Yadav; Valeria Judkowski; Malin Flodstrom-Tullberg; Lori Sterling; William L Redmond; Linda Sherman; Nora Sarvetnick
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

7.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.

Authors:  Hélène Bour-Jordan; Benoît L Salomon; Heather L Thompson; Gregory L Szot; Matthew R Bernhard; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Transcriptional regulation of th2 differentiation by inducible costimulator.

Authors:  Roza I Nurieva; Julie Duong; Hiroko Kishikawa; Umberto Dianzani; Jose M Rojo; I cheng Ho; Richard A Flavell; Chen Dong
Journal:  Immunity       Date:  2003-06       Impact factor: 31.745

9.  On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity.

Authors:  Kevin L Legge; Randal K Gregg; Roberto Maldonado-Lopez; Lequn Li; Jacque C Caprio; Muriel Moser; Habib Zaghouani
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

10.  Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice.

Authors:  Valentina Di Caro; Brett Phillips; Carl Engman; Jo Harnaha; Massimo Trucco; Nick Giannoukakis
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

View more
  5 in total

1.  Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.

Authors:  S Quan; J R Sheng; P M Abraham; B Soliven
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

2.  IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration.

Authors:  Collin-Jamal Smith; Denise E Allard; Yan Wang; James F Howard; Stephanie A Montgomery; Maureen A Su
Journal:  J Immunol       Date:  2018-01-24       Impact factor: 5.422

Review 3.  Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies.

Authors:  Jolien Wolbert; Mandy I Cheng; Gerd Meyer zu Horste; Maureen A Su
Journal:  JCI Insight       Date:  2020-02-13

Review 4.  Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Authors:  Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-15

Review 5.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.